Clinical Vignette in Antiretroviral Therapy: Jaundice

Weisiger RA . Laboratory tests in liver disease and the approach to the patient with abnormal tests. In: Goldman L , Bennett J , eds. Cecil Textbook of Medicine 21st ed. Philadelphia: WB Saunders; 2000:757-779.

Chung R , Sherman K . Hepatic and hepatobiliary diseases. In: Dolin R , Masur H , Saag M , eds. AIDS Therapy 2nd ed. New York: Churchill Livingstone; 2003:902-920.

Talal A , Dieterich D . Gastrointestinal and hepatic manifestations of HIV infection. In: Sande M , Volberding P , eds. The Medical Management of AIDS 6th ed. Philadelphia: WB Saunders; 1999:195-216.

Cello JP . Acquired immunodeficiency syndrome cholangiopathy: Spectrum of disease. Am J Med 1989;86(5):539-546.

Nash JA , Cohen SA . Gallbladder and biliary tract disease in AIDS. Gastroenterol Clin North Am 1997;26(2):323-335.

Cappell MS , Schwartz MS , Biempica L . Clinical utility of liver biopsy in patients with serum antibodies to the human immunodeficiency virus. Am J Med 1990;88(2):123-130.

Cavicchi M , Pialoux G , Carnot F , et al. Value of liver biopsy for the rapid diagnosis of infection in human immunodeficiency virus-infected patients who have unexplained fever and elevated serum levels of alkaline phosphatase or gamma-glutamyl transferase. Clin Infect Dis 1995;20(3):606-610.

O’Mara EM , Mummaneni V , Burchell B , et al. Relationship between uridine diphosphate-glucuronsyl transferase (UDP-GT) 1A1 genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinavir. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, 2000. Toronto, Ontario, Canada. (Abstract 1645).

Dieterich DT , Fischl M , Sepulveda G . The safety/efficacy of protease inhibitors (PIs) in hepatitis C (HCV) co-infected patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 27-30, 2002. San Diego, California. (Abstract H-1729).

Badaro R , DeJesus E , Lazzarin A , et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16 week results from BMS AI424-045. 2nd IAS Conference on HIV Pathogensis and Treatment. July 13-16, 2003. Paris, France. (Abstract 118).

Palmon R , Koo BC , Shoultz DA , Dieterich DT . Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29(4):340-345.

Sulkowski MS , Thomas DL , Mehta SH , Chaisson RE , Moore RD . Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002;35(1):182-189.

Sulkowski MS , Thomas DL , Chaisson RE , Moore RD . Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283(1):74-80.

Reisler R , Liou S , Servoss J , et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials. 1st IAS Conference on HIV Pathogenesis and Treatment. July 8-11, 2001. Buenos Aires, Argentina. (Abstract 43).